netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 31 to 60 of 96

New Newer Older Oldest

Details
UPD Pembrolizumab (Keytruda®) NICE TA683
17/11/2022 14:27:42
(DavidS )
LDL Link Added : NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer : https://www.nice.org.uk/guidance/ta683
17/11/2022 14:27:09
(DavidS )
UPD sitematrix Changed from 0 to
15/11/2022 16:59:48
(DavidS )
UPD FurtherInformation Changed from
15/11/2022 16:59:48
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA837
15/11/2022 16:59:48
(DavidS )
LDL Link Added : NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma : https://www.nice.org.uk/guidance/ta837
15/11/2022 16:59:22
(DavidS )
LDL Link Added : NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma : https://www.nice.org.uk/guidance/ta830
15/11/2022 16:50:44
(DavidS )
UPD sitematrix Changed from 0 to
15/11/2022 16:50:25
(DavidS )
UPD FurtherInformation Changed from
15/11/2022 16:50:25
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA830
15/11/2022 16:50:25
(DavidS )
UPD sitematrix Changed from 0 to
27/07/2022 15:35:58
(DavidS )
UPD BlueTeq Changed from N to Y
27/07/2022 15:35:58
(DavidS )
UPD Pembrolizumab (Keytruda®) updated
27/07/2022 15:35:58
(DavidS )
UPD Published from Draft Mode
27/07/2022 15:11:25
(LoweryM )
LDL Link Added : NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer : https://www.nice.org.uk/guidance/ta801
15/07/2022 10:45:56
(DavidS )
UPD sitematrix Changed from 0 to
15/07/2022 10:45:29
(DavidS )
UPD isDraft Changed from N to Y
15/07/2022 10:45:29
(DavidS )
UPD FurtherInformation Changed from
15/07/2022 10:45:29
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA801
15/07/2022 10:45:29
(DavidS )
UPD Published from Draft Mode
12/05/2022 11:04:24
(DavidS )
UPD sitematrix Changed from 0 to
26/04/2022 12:52:56
(DavidS )
UPD FurtherInformation Changed from
26/04/2022 12:52:56
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA772. APC - APril 2022
26/04/2022 12:52:56
(DavidS )
LDL Link Added : NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies : https://www.nice.org.uk/guidance/ta772
26/04/2022 12:52:07
(DavidS )
LDL Link Added : NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer : https://www.nice.org.uk/guidance/ta770
26/04/2022 12:51:22
(DavidS )
UPD sitematrix Changed from 0 to
26/04/2022 12:50:59
(DavidS )
UPD FurtherInformation Changed from
26/04/2022 12:50:59
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA770. APC - APril 2022
26/04/2022 12:50:59
(DavidS )
LDL Link Added : NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma : https://www.nice.org.uk/guidance/ta766
26/04/2022 12:09:49
(DavidS )
UPD sitematrix Changed from 0 to
26/04/2022 12:09:28
(DavidS )

 

 
netFormulary